482,055 Shares in Zimmer Biomet Holdings, Inc. $ZBH Acquired by Mitsubishi UFJ Asset Management Co. Ltd.

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 482,055 shares of the medical equipment provider’s stock, valued at approximately $41,500,000. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.25% of Zimmer Biomet at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the stock. DV Equities LLC bought a new position in Zimmer Biomet in the 4th quarter worth about $25,000. Monetary Solutions Ltd purchased a new position in Zimmer Biomet in the fourth quarter worth about $30,000. Gen Wealth Partners Inc purchased a new stake in shares of Zimmer Biomet during the fourth quarter valued at approximately $31,000. Elevation Wealth Partners LLC increased its position in shares of Zimmer Biomet by 145.9% during the second quarter. Elevation Wealth Partners LLC now owns 386 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 229 shares in the last quarter. Finally, Cornerstone Financial Management LLC purchased a new position in Zimmer Biomet in the 4th quarter worth approximately $37,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Price Performance

Shares of Zimmer Biomet stock opened at $100.65 on Thursday. Zimmer Biomet Holdings, Inc. has a one year low of $79.12 and a one year high of $108.29. The stock’s fifty day moving average is $92.16 and its 200 day moving average is $90.85. The stock has a market cap of $19.20 billion, a P/E ratio of 24.49, a P/E/G ratio of 2.70 and a beta of 0.45. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.94 and a current ratio of 1.69.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to analyst estimates of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.Zimmer Biomet’s revenue for the quarter was up 4.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. Sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.53 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, July 31st. Investors of record on Thursday, June 25th were paid a dividend of $0.24 per share. The ex-dividend date was Thursday, June 25th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s payout ratio is 23.36%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Stifel Nicolaus upped their price objective on Zimmer Biomet from $105.00 to $110.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. BMO Capital Markets reissued a “market perform” rating and issued a $96.00 target price on shares of Zimmer Biomet in a report on Thursday, August 6th. Sanford C. Bernstein upped their price target on Zimmer Biomet from $91.00 to $93.00 and gave the company a “market perform” rating in a report on Thursday, August 6th. Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research report on Thursday, August 6th. Finally, Weiss Ratings upgraded Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, August 4th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $104.42.

Insider Transactions at Zimmer Biomet

In related news, insider Sang Yi sold 5,000 shares of the stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $82.64, for a total value of $413,200.00. Following the completion of the sale, the insider directly owned 27,251 shares of the company’s stock, valued at approximately $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 1.28% of the company’s stock.

Zimmer Biomet Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.